vs
Side-by-side financial comparison of CaliberCos Inc. (CWD) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $4.1M, roughly 1.3× CaliberCos Inc.). CaliberCos Inc. runs the higher net margin — -188.3% vs -507.8%, a 319.4% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -52.5%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -57.6%).
CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
CWD vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.1M | $5.5M |
| Net Profit | $-7.7M | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | -196.6% | -516.0% |
| Net Margin | -188.3% | -507.8% |
| Revenue YoY | -52.5% | 171.3% |
| Net Profit YoY | 32.2% | -48.3% |
| EPS (diluted) | $1.95 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.1M | $5.5M | ||
| Q3 25 | $3.6M | $0 | ||
| Q2 25 | $5.1M | $2.0M | ||
| Q1 25 | $7.3M | $2.3M | ||
| Q4 24 | $8.7M | $2.0M | ||
| Q3 24 | $11.3M | $1.8M | ||
| Q2 24 | $8.2M | $1.1M | ||
| Q1 24 | $23.0M | $3.4M |
| Q4 25 | $-7.7M | $-27.9M | ||
| Q3 25 | $-4.4M | $-32.7M | ||
| Q2 25 | $-5.3M | $-26.9M | ||
| Q1 25 | $-4.4M | $-21.5M | ||
| Q4 24 | $-11.4M | $-18.8M | ||
| Q3 24 | $146.0K | $-25.5M | ||
| Q2 24 | $-4.7M | $-20.9M | ||
| Q1 24 | $-3.8M | $-24.1M |
| Q4 25 | -196.6% | -516.0% | ||
| Q3 25 | -129.6% | — | ||
| Q2 25 | -112.4% | -1347.1% | ||
| Q1 25 | -62.7% | -930.5% | ||
| Q4 24 | -236.8% | -985.8% | ||
| Q3 24 | 0.0% | -1448.4% | ||
| Q2 24 | -65.0% | -1915.4% | ||
| Q1 24 | -22.9% | -713.3% |
| Q4 25 | -188.3% | -507.8% | ||
| Q3 25 | -120.2% | — | ||
| Q2 25 | -104.5% | -1353.6% | ||
| Q1 25 | -60.7% | -935.2% | ||
| Q4 24 | -247.6% | -929.0% | ||
| Q3 24 | 1.3% | -1427.5% | ||
| Q2 24 | -57.8% | -1882.0% | ||
| Q1 24 | -16.6% | -705.4% |
| Q4 25 | $1.95 | $-0.08 | ||
| Q3 25 | $-1.65 | $-0.09 | ||
| Q2 25 | $-4.15 | $-0.09 | ||
| Q1 25 | $-3.85 | $-0.08 | ||
| Q4 24 | $-10.15 | $-0.07 | ||
| Q3 24 | $0.12 | $-0.10 | ||
| Q2 24 | $-4.34 | $-0.09 | ||
| Q1 24 | $-3.53 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.9M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3M | $246.9M |
| Total Assets | $135.4M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9M | $319.8M | ||
| Q3 25 | $10.9M | $297.3M | ||
| Q2 25 | $683.0K | $312.8M | ||
| Q1 25 | $1.6M | $116.6M | ||
| Q4 24 | $2.3M | $139.0M | ||
| Q3 24 | $1.6M | $157.7M | ||
| Q2 24 | $1.8M | $172.7M | ||
| Q1 24 | $2.1M | $124.0M |
| Q4 25 | $1.3M | $246.9M | ||
| Q3 25 | $4.2M | $219.0M | ||
| Q2 25 | $-19.9M | $248.7M | ||
| Q1 25 | $-15.8M | $55.1M | ||
| Q4 24 | $-12.6M | $71.5M | ||
| Q3 24 | $-3.8M | $88.8M | ||
| Q2 24 | $-4.7M | $108.9M | ||
| Q1 24 | $-745.0K | $53.8M |
| Q4 25 | $135.4M | $343.3M | ||
| Q3 25 | $82.6M | $316.6M | ||
| Q2 25 | $59.3M | $333.3M | ||
| Q1 25 | $103.6M | $138.4M | ||
| Q4 24 | $105.5M | $160.4M | ||
| Q3 24 | $158.6M | $180.2M | ||
| Q2 24 | $195.2M | $200.4M | ||
| Q1 24 | $201.5M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.1M | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-12.1M | $-26.7M | ||
| Q3 25 | $-4.6M | $-24.2M | ||
| Q2 25 | $-1.2M | $-20.2M | ||
| Q1 25 | $-1.7M | $-22.0M | ||
| Q4 24 | $555.0K | $-18.3M | ||
| Q3 24 | $-74.0K | $-21.6M | ||
| Q2 24 | $1.4M | $-21.5M | ||
| Q1 24 | $-1.5M | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.51× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
